Jiade Yu, MD, on the Future of Chronic Hand Eczema Treatment

At RAD 2025, Jiade Yu, MD, discussed the evolving landscape of chronic hand eczema treatment and emphasized the urgent need for real-world data. In this follow-up interview with Patient Care, Dr Yu shares his hopes for the year ahead, including expanded clinical evidence for topical and systemic therapies like delgocitinib, ruxolitinib, and dupilumab. He also explains how better disease recognition and patient subtyping could lead to more personalized and effective care.

Jiade Yu, MD, is an assistant professor of dermatology at Harvard Medical School and the director of the Occupational and Contact Dermatitis Clinic at Massachusetts General Hospital in Boston.

The following transcript has been edited for clarity, style, and length.

Patient Care: If you were giving this presentation next year, what do you hope will be different?

Jiade Yu, MD: I hope by next year we’ll have much more real-world data on the different treatment options for chronic hand eczema. That includes emerging therapies like delgocitinib, which is showing promise, as well as data from studies on ruxolitinib. There’s also some early evidence on systemic treatments like dupilumab being used in this context.

What I’m really hoping for is a broader understanding and appreciation of chronic hand eczema as a distinct condition. With that, we’ll be able to better categorize patients into subtypes, tailor treatments more effectively, and identify who responds to what. From there, we can build more precise and impactful treatment strategies.